InMed Pharmaceuticals Inc. (INM) Financial Analysis & Valuation | Quarter Chart
InMed Pharmaceuticals Inc. (INM)
INMPrice: $0.8
Fair Value: 🔒
🔒score
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is al... more
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabi... more
Description
Shares
| Market Cap | $1.45M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | CA | CEO | Eric A. Adams Chem. |
| IPO Date | 2014-05-05 | CAGR | 0.37% |
| Employees | 13 | Website | www.inmedpharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
INM chart loading...
Fundamentals
Technicals
| Enterprise Value | $-8.65M | P/E Ratio | -0.28 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | — |
| P/CF Ratio | — | P/FCF Ratio | — |
| EPS | $-2.88 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 17880.83% | Gross Margin | 0.34% |
| Operating Margin | -1.56% | Profit Margin | -1.65% |
| ROE | -0.93% | ROA | -0.52% |
| ROCE | -0.56% | Current Ratio | 6.99 |
| Quick Ratio | 6.47 | Cash Ratio | 6.02 |
| Debt/Equity | 0.06 | Interest Coverage | -20.78 |
| Altman Z Score | -10.4 | Piotroski Score | 4 |